The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer
- 25 April 2015
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 36 (7) , 4939-4948
Abstract
Overexpression of cyclin-dependent kinase 1 (CDK1) has been noted to correlation with several human cancers. However, the effects of CDK1 on ovarian cancer development remain unclear. The aim of this study was to examine the effect of CDK1 and related mechanism in the proliferation and resistance to chemotherapeutic drugs of epithelial ovarian cancer (EOC). Immunohistochemical analysis was performed in 119 human ovarian cancer samples, and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for CDK1 in EOC samples and cell lines to evaluate their protein levels and molecular interaction. Kaplan-Meier survival analysis showed that strong expression of CDK1 exhibited a significant correlation with poor prognosis in human EOC (P = 0.02). Meanwhile, we found that knockdown CDK1 by shCDK1 promoted the apoptosis rate and increased the sensitivity to chemotherapy drugs. Thus, CDK1 might serve as a prognostic marker, and it might be of great value for experimental therapies in EOC.Keywords
This publication has 20 references indexed in Scilit:
- Treatment options in recurrent ovarian cancer: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology, 2014
- Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cellsBMC Cancer, 2014
- Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cellsJournal of Ovarian Research, 2013
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancerBritish Journal of Cancer, 2011
- Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancersAnnals of Oncology, 2011
- Physiological Relevance of Cell Cycle KinasesPhysiological Reviews, 2011
- Growth and division—not a one-way roadCurrent Opinion in Cell Biology, 2010
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal populationInternational Journal of Gynecological Cancer, 2004